Every SEC Form 3/4/5 on record for this filer (CIK 1569226) — 9 issuers, 10 transactions. Section-16 filings only: what they filed, not a biography, and titles are as filed on their latest form at each issuer.
| Ticker | Company | Role as filed | On file | Forms | Open-market net |
|---|---|---|---|---|---|
| NUVL | Nuvalent, Inc. | Director | 2021-07-28 → 2026-06-18 | 7 | — |
| AURA | Aura Biosciences, Inc. | Director | 2021-10-28 → 2026-06-15 | 7 | — |
| TRML | Tourmaline Bio, Inc. | Director | 2023-10-23 → 2025-10-28 | 4 | — |
| ALMS | ALUMIS INC. | Director | 2024-06-27 → 2025-08-01 | 3 | — |
| INVA | Innoviva, Inc. | Director · lapsed | 2023-01-06 → 2024-06-20 | 3 | — |
| SQZ | SQZ Biotechnologies Co | Director · lapsed | 2020-10-29 → 2023-06-15 | 5 | — |
| TALS | Talaris Therapeutics, Inc. | Director · lapsed | 2021-05-06 → 2023-06-14 | 3 | — |
| DNAB | Social Capital Suvretta Holdings Corp. II | Director · lapsed | 2021-06-29 → 2021-06-29 | 1 | — |
| NTLA | Intellia Therapeutics, Inc. | Chief Financial & Stategy Offr · lapsed | 2016-05-05 → 2016-05-05 | 1 | — |
No open-market buy or sale on record — only grants, exercises, withholding or gifts. Switch to “All forms” to see them.
5 of 9 issuers are covered and open a security page; the rest are on file here only.
